Market research
KDMN Kadmon Holdings Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 12.1
- Dividend yield
- 0.0%
- Beta
- 1.12
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US48283N1063
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 12.1
- Dividend yield
- 0.0%
- Beta
- 1.12
About
About Kadmon Holdings Inc
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. Kadmon Holdings, Inc., was incorporated in 2010 and is headquartered in New York, New York. As of November 9, 2021, Kadmon Holdings, Inc. operates as a subsidiary of Sanofi.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the KDMN discussion.
5 years, 4 months ago
Kadmon Holdings, Inc is currently in a long term downtrend where the price is trading 8.6% below its 200 day moving average.
From a valuation standpoint, the stock is 94.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 79.2.
Kadmon Holdings, Inc's total revenue sank by 86.0% to $615K since the same quarter in the previous year.
Its net income has dropped by 137.6% to $-28M since the same quarter in the previous year.
Finally, its free cash flow fell by 63.9% to $-27M since the same quarter in the previous year.
Based on the above factors, Kadmon Holdings, Inc gets an overall score of 1/5.